Lundbeck and partner present "slam-dunk" data for new Alzheimer's drug

Analysts are excited about Lundbeck’s final data presentation for Rexulti, which has reached all endpoints in a phase III study.

Photo: Jens Dresling

The new data that Lundbeck and Otsuka have released on their Alzheimer’s candidate Rexulti has eliminated any doubt about the treatment’s potential, Danish financial daily Børsen writes.

”The data is a ’slam dunk’ which eliminates the risk of not getting an approval and reveals blockbuster potential,” says James Gordon, pharmaceutical analyst at JP Morgan, according to the media.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs